Tag Archives: Pancreatic

AstraZeneca, Merck's Lynparza posts pancreatic cancer win in another PARP-class first

AstraZeneca and Merck’s Lynparza has already led its class into two disease areas, and now it’s looking to make it three. Tuesday, the companies said their PARP inhibitor had topped placebo at staving off progression of tough-to-treat pancreatic cancer in patients with germline BRCA-mutated forms of the disease. The phase 3 study, dubbed POLO, examined Lynparza in… Read More »